Clinical trial
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia…
NCT00034684 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00034684 |
|---|---|
| Title | Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) |
| Official title | Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myeloid, Chronic, Blast Crisis, Lymphocytic |
| Intervention type | Drug |
| Interventions | Farnesyl Protein Transferase Inhibitor |
| Enrollment | 132 |
| Start date | Jul 1, 2001 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | May 2, 2002 |
| Last update posted | Jun 17, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: